Literature DB >> 16723179

The effect of perospirone on auditory P300 in schizophrenia: a preliminary study.

Tsuyoshi Araki1, Kiyoto Kasai, Mark A Rogers, Nobumasa Kato, Akira Iwanami.   

Abstract

The present study was performed to determine the effect of perospirone, a novel antipsychotic drug with D(2)/5-HT(2A) antagonist and partial 5-HT(1A) agonist properties, on auditory P300 in eight patients with chronic schizophrenia. Switching to an equivalent dose of perospirone from prior antipsychotic medication was associated with a significant improvement in the negative symptoms of the positive and negative syndrome scale (PANSS). The change in P300 amplitude following a switch to perospirone correlated significantly with the improvement of general psychopathology symptoms, as well as with the change in scores on items of delusions, hallucinatory behavior, emotional withdrawal, depression, poor attention, and disturbance of volition. These results suggest that clinical improvement in response to perospirone in some patients may, at least in part, be mediated through cognitive change indexed by P300 in chronic schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723179     DOI: 10.1016/j.pnpbp.2006.04.009

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  3 in total

1.  Effect of the novel antipsychotic drug perospirone on P-glycoprotein function and expression in Caco-2 cells.

Authors:  Yan-Gang Zhou; Kun-Yan Li; Huan-De Li
Journal:  Eur J Clin Pharmacol       Date:  2008-05-14       Impact factor: 2.953

2.  Meta-analysis of studies in China about changes in P300 latency and amplitude that occur in patients with schizophrenia during treatment with antipsychotic medication.

Authors:  Liang Su; Yiyun Cai; Shenxun Shi; Liwei Wang
Journal:  Shanghai Arch Psychiatry       Date:  2012-08

Review 3.  Electrophysiological Evidence in Schizophrenia in Relation to Treatment Response.

Authors:  Kazuki Sueyoshi; Tomiki Sumiyoshi
Journal:  Front Psychiatry       Date:  2018-06-13       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.